Eikonoklastes Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$16.1M
- Investors
-
4
Eikonoklastes Therapeutics General Information
Description
Developer of disruptive therapies designed to assist in the treatment of solid tumors and other pathologic conditions. The company's immunotherapies target the cell-surface receptor by utilizing a recombinant fusion protein, enabling healthcare professionals to treat triple-negative breast cancer, ovarian cancer, metastatic melanoma, and a broad range of other solid tumors.
Contact Information
Website
www.eikonoklastes.comCorporate Office
- 2356 Park Avenue
- Unit 17
- Cincinnati, OH 45206
- United States
Corporate Office
- 2356 Park Avenue
- Unit 17
- Cincinnati, OH 45206
- United States
Eikonoklastes Therapeutics Timeline
Eikonoklastes Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B2) | 05-Oct-2026 | $16.1M | Completed | Pre-Clinical Trials | ||
| 3. Later Stage VC (Series B1) | 25-Jun-2024 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 06-May-2021 | $3.18M | $4.28M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 04-Mar-2020 | $1.1M | $1.1M | Completed | Pre-Clinical Trials |
Eikonoklastes Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 3,890,977 | $0.000010 | $1.34 | $1.34 | 1x | $1.34 | 13.28% | |
| Seed | 3,228,567 | $0.000010 | $0.7 | $0.7 | 1x | $0.7 | 11.02% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Eikonoklastes Therapeutics Comparisons
Industry
Financing
Details
Eikonoklastes Therapeutics Competitors (3)
One of Eikonoklastes Therapeutics’s 3 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Bolt Biotherapeutics | Formerly VC-backed | Redwood City, CA | ||||
| Immunicom | Venture Capital-Backed | San Diego, CA |
Eikonoklastes Therapeutics Signals
Eikonoklastes Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Elkstone | Family Office | Minority | ||
| JobsOhio Ventures | Venture Capital | Minority | ||
| CincyTech | Venture Capital | Minority | ||
| R1 Capital (Columbus) | Venture Capital | Minority |
Eikonoklastes Therapeutics FAQs
-
When was Eikonoklastes Therapeutics founded?
Eikonoklastes Therapeutics was founded in 2019.
-
Where is Eikonoklastes Therapeutics headquartered?
Eikonoklastes Therapeutics is headquartered in Cincinnati, OH.
-
What is the size of Eikonoklastes Therapeutics?
Eikonoklastes Therapeutics has 8 total employees.
-
What industry is Eikonoklastes Therapeutics in?
Eikonoklastes Therapeutics’s primary industry is Drug Discovery.
-
Is Eikonoklastes Therapeutics a private or public company?
Eikonoklastes Therapeutics is a Private company.
-
What is the current valuation of Eikonoklastes Therapeutics?
The current valuation of Eikonoklastes Therapeutics is .
-
What is Eikonoklastes Therapeutics’s current revenue?
The current revenue for Eikonoklastes Therapeutics is .
-
How much funding has Eikonoklastes Therapeutics raised over time?
Eikonoklastes Therapeutics has raised $27.5M.
-
Who are Eikonoklastes Therapeutics’s investors?
Elkstone, JobsOhio Ventures, CincyTech, and R1 Capital (Columbus) have invested in Eikonoklastes Therapeutics.
-
Who are Eikonoklastes Therapeutics’s competitors?
CytomX Therapeutics, Bolt Biotherapeutics, and Immunicom are competitors of Eikonoklastes Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process